Akt-mediated cardioprotective effects of aldosterone in type 2 diabetic mice

FASEB Journal

Volumn 28, Issue 6, 2014, Pages 2430-2440

  Fazal, Loubina ^a,c   Azibani, Feriel ^a   Bihry, Nicolas ^a,b   Coutance, Guillaume ^a,c   Polidano, Evelyne ^a   Merval, Régine ^a   Vodovar, Nicolas ^a   Launay, Jean Marie ^a,b,c   Delcayre, Claude ^a,c   Samuel, Jane Lise ^a,b,c  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Heart; IGF 1 receptor; Insulin; Physiopathology

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; FEMALE; HEART PROTECTION; IMMUNOBLOTTING; IMMUNOHISTOLOGY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

HEART; IGF-1 RECEPTOR; INSULIN; PHYSIOPATHOLOGY;

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; HEART; HYPERALDOSTERONISM; INSULIN RESISTANCE; MALE; MICE; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1;

EID: 84901851692     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-239822     Document Type: Article

References (36)

1. Cohen-Solal, A., Beauvais, F., and Logeart, D. (2008) Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J. Card. Fail. 14, 615-625
2. Gray, S., and Kim, J. K. (2011) New insights into insulin resistance in the diabetic heart. TEM 22, 394-403
3. Lastra, G., Dhuper, S., Johnson, M. S., and Sowers, J. R. (2010) Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat. Rev. Cardiol. 7, 577-584
4. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (Pubitemid 29407370)
5. Krug, A. W., and Ehrhart-Bornstein, M. (2008) Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 51, 1252-1258 (Pubitemid 351555932)
6. Zannad, F., Gattis Stough, W., Rossignol, P., Bauersachs, J., McMurray, J. J., Swedberg, K., Struthers, A. D., Voors, A. A., Ruilope, L. M., Bakris, G. L., O'Connor, C. M., Gheorghiade, M., Mentz, R. J., Cohen-Solal, A., Maggioni, A. P., Beygui, F., Filippatos, G. S., Massy, Z. A., Pathak, A., Pina, I. L., Sabbah, H. N., Sica, D. A., Tavazzi, L., and Pitt, B. (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur. Heart J. 33, 2782-2795
7. Maron, B. A., and Leopold, J. A. (2008) Mineralocorticoid receptor antagonists and endothelial function. Curr. Opin. Investig. Drugs 9, 963-969
8. Davies, J. I., Band, M., Morris, A., and Struthers, A. D. (2004) Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47, 1687-1694 (Pubitemid 40022402)
9. Messaoudi, S., Milliez, P., Samuel, J. L., and Delcayre, C. (2009) Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J. 23, 2176-2185
10. Garnier, A., Bendall, J. K., Fuchs, S., Escoubet, B., Rochais, F., Hoerter, J., Nehme, J., Ambroisine, M. L., De Angelis, N., Morineau, G., d'Estienne, P., Fischmeister, R., Heymes, C., Pinet, F., and Delcayre, C. (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819-1825 (Pubitemid 39299224)
11. Milliez, P., Messaoudi, S., Nehme, J., Rodriguez, C., Samuel, J. L., and Delcayre, C. (2009) Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. 296, H435-H441
12. Azibani, F., Devaux, Y., Coutance, G., Schlossarek, S., Polidano, E., Fazal, L., Merval, R., Carrier, L., Solal, A. C., Chatziantoniou, C., Launay, J. M., Samuel, J. L., and Delcayre, C. (2012) Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PLoS One 7, e38197
13. Park, C. W., Kim, H. W., Lim, J. H., Yoo, K. D., Chung, S., Shin, S. J., Chung, H. W., Lee, S. J., Chae, C. B., Kim, Y. S., and Chang, Y. S. (2009) Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice. Diabetes 58, 2666-2676
14. Jiang, T., Zhuang, J., Duan, H., Luo, Y., Zeng, Q., Fan, K., Yan, H., Lu, D., Ye, Z., Hao, J., Feng, J., Yang, D., and Yan, X. (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120, 2330-2339
15. Chatzigeorgiou, A., Halapas, A., Kalafatakis, K., and Kamper, E. (2009) The use of animal models in the study of diabetes mellitus. In Vivo 23, 245-258
16. Rees, D. A., and Alcolado, J. C. (2005) Animal models of diabetes mellitus. Diabetic Med. 22, 359-370 (Pubitemid 40516231)
17. Bonnard, C., Durand, A., Peyrol, S., Chanseaume, E., Chauvin, M. A., Morio, B., Vidal, H., and Rieusset, J. (2008) Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J. Clin. Invest. 118, 789-800 (Pubitemid 351206566)
18. Liu, J., Divoux, A., Sun, J., Zhang, J., Clement, K., Glickman, J. N., Sukhova, G. K., Wolters, P. J., Du, J., Gorgun, C. Z., Doria, A., Libby, P., Blumberg, R. S., Kahn, B. B., Hotamisligil, G. S., and Shi, G. P. (2009) Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 15, 940-945
19. Kim, J. K., Kim, H. J., Park, S. Y., Cederberg, A., Westergren, R., Nilsson, D., Higashimori, T., Cho, Y. R., Liu, Z. X., Dong, J., Cline, G. W., Enerback, S., and Shulman, G. I. (2005) Adipocytespecific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance. Diabetes 54, 1657-1663 (Pubitemid 40770755)
20. Daniels, A., van Bilsen, M., Goldschmeding, R., van der Vusse, G. J., and van Nieuwenhoven, F. A. (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol. (Oxf.) 195, 321-338
21. Swynghedauw, B. (1999) Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79, 215-262
22. Koitabashi, N., and Kass, D. A. (2012) Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat. Rev. Cardiol. 9, 147-157
23. Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., Kutschera, S., Bartels, S., Appak, S., Besemfelder, E., Terhardt, D., Chavakis, E., Wieland, T., Klein, C., Thomas, M., Uemura, A., Goerdt, S., and Augustin, H. G. (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest. 122, 1991-2005
24. Michel, F., Ambroisine, M. L., Duriez, M., Delcayre, C., Levy, B. I., and Silvestre, J. S. (2004) Aldosterone enhances ischemiainduced neovascularization through angiotensin II-dependent pathway. Circulation 109, 1933-1937 (Pubitemid 38544481)
25. Kaji, K., Yoshiji, H., Kitade, M., Ikenaka, Y., Noguchi, R., Shirai, Y., Yoshii, J., Yanase, K., Namisaki, T., Yamazaki, M., Tsujimoto, T., Kawaratani, H., and Fukui, H. (2010) Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol. Res. 40, 540-549
26. Hill, J. A., and Olson, E. N. (2008) Cardiac plasticity. N. Engl. J. Med. 358, 1370-1380
27. Huynh, K., Kiriazis, H., Du, X. J., Love, J. E., Jandeleit-Dahm, K. A., Forbes, J. M., McMullen, J. R., and Ritchie, R. H. (2012) Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 55, 1544-1553
28. Burton, T. R., and Gibson, S. B. (2009) The role of Bcl-2 family member BNIP3 in cell death and disease: NIPping at the heels of cell death. Cell Death Differ. 16, 515-523
29. Xue, Q., Nagy, J. A., Manseau, E. J., Phung, T. L., Dvorak, H. F., and Benjamin, L. E. (2009) Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler. Thromb. Vasc. Biol. 29, 1172-1178
30. Karar, J., and Maity, A. (2011) PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51
31. O'Neill, B. T., and Abel, E. D. (2005) Akt1 in the cardiovascular system: friend or foe? J. Clin. Invest. 115, 2059-2064 (Pubitemid 41134142)
32. Cook, S. A., Varela-Carver, A., Mongillo, M., Kleinert, C., Khan, M. T., Leccisotti, L., Strickland, N., Matsui, T., Das, S., Rosenzweig, A., Punjabi, P., and Camici, P. G. (2010) Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 31, 100-111
33. Laustsen, P. G., Russell, S. J., Cui, L., Entingh-Pearsall, A., Holzenberger, M., Liao, R., and Kahn, C. R. (2007) Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell. Biol. 27, 1649-1664
34. Abbas, A., Imrie, H., Viswambharan, H., Sukumar, P., Rajwani, A., Cubbon, R. M., Gage, M., Smith, J., Galloway, S., Yuldeshava, N., Kahn, M., Xuan, S., Grant, P. J., Channon, K. M., Beech, D. J., Wheatcroft, S. B., and Kearney, M. T. (2011) The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes 60, 2169-2178
35. Cascella, T., Radhakrishnan, Y., Maile, L. A., Busby, W. H., Jr., Gollahon, K., Colao, A., and Clemmons, D. R. (2010) Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Endocrinology 151, 5851-5864
36. Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., and Sasaoka, T. (2010) Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151, 2040-2049